All the latest news, press relseases and company updates.
Friday 25 June Today we are excited to announce positive top-line data from our Phase 3 head-to-head trial of trientine tetrahydrochloride and d-penicillamine. This is the first trial of its…
JUNE 25, 2021 - ORPHAN DISEASES — CHELATE trial confirmed trientine tetrahydrochloride was non-inferior to d-Penicillamine and met the primary endpoint of Non-Ceruloplasmin Copper (NCC) levels as a maintenance therapy…
Find out more about Orphalan, who we are and what we do
Our research and development strategy is focused on the patient
Find out more about Orphalan and get in touch.